Foscarnet en la retinitis por citomegalovirus
- Suárez de Figueroa,
- García, C.
- Montilla, P.
- Hermida, J.M.
ISSN: 0365-6691
Année de publication: 1991
Volumen: 60
Número: 3
Pages: 339-344
Type: Article
D'autres publications dans: Archivos de la Sociedad Española de Oftalmologia
Résumé
Six patients with active C.M.V. retinitis and acquired immune deficiency syndrome were treated with the new antiviral drug, Foscarnet (trisudium phosphonoformate). The rate of relapse on maintenance therapy with 100 mg/kg/24 h. seven days per week, was 33% (2/6). In contrast to Ganciclovir, Foscarnet did not induce neutropenia but it produced kidney toxicity that led to reversible renal insufficiency in one case. A decrease of hemoglobin concentration greater than 20%, changes in serum calcium and phosphorous levels were not noted in any patient.